Doctor's Deposition To Be Shown In Fosamax Trial

Law360, New York (August 20, 2009, 4:24 PM EDT) -- A judge has denied pharmaceutical giant Merck & Co.'s request to toss out the testimony of a doctor who says osteoporosis drug Fosamax caused the plaintiff of a bellwether product liability trial to develop a degenerative bone disease.

Judge John Keenan of the U.S. District Court for the Southern District of New York ruled on the motion from the bench during trial Aug. 19, according to lawyers from both sides.

A Merck attorney called the issue of Dr. Patrick Anastasio's deposition “one of a number of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.